|
28 Aug 2022 |
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
|
|
27 Aug 2022 |
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
|
|
27 Aug 2022 |
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
|
|
25 Aug 2022 |
Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader
|
|
25 Aug 2022 |
Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors
|
|
23 Aug 2022 |
K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001
|
|
23 Aug 2022 |
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
|
|
23 Aug 2022 |
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
|
|
23 Aug 2022 |
Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
|
|
22 Aug 2022 |
Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT
|
|
22 Aug 2022 |
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
|
|
19 Aug 2022 |
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer
|
|
19 Aug 2022 |
BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
|
|
19 Aug 2022 |
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
|
|
18 Aug 2022 |
CG Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Ivaltinostat for the Treatment of Pancreatic Adenocarcinoma
|
|
18 Aug 2022 |
European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma
|
|
18 Aug 2022 |
Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
|
|
18 Aug 2022 |
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
|
|
18 Aug 2022 |
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
|
|
18 Aug 2022 |
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
|
|
17 Aug 2022 |
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
|
|
17 Aug 2022 |
Sanofi provides update on amcenestrant clinical development program
|
|
16 Aug 2022 |
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
|
|
16 Aug 2022 |
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
|
|
16 Aug 2022 |
Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases
|
